[Analysis of clinical effects of a concurrent CDDP/5-FU therapy on inoperable colon cancer].
The mechanisms of synergic effects on cancer cells, the rational dose schedules resulting from these action mechanisms, and actual clinical results for inoperable colon cancer patients by a concurrent CDDP/5-FU therapy, are described. We analyzed the clinical results on the basis on the literature dealing with concurrent CDDP/5-FU therapy for inoperable colon cancer patients. This analysis suggested that some modified dose schedules of CDDP and 5-FU for inoperable colon cancer patients made no difference in response rates, survival times or adverse effects. Concurrent low-dose CDDP/5-FU therapy for inoperable colon cancer patients is now awaited in Japan.
Akazawa
S
S
Dept. of Gastroenterology, Saitama Cancer Center, Japan.
Yamato
A
A
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004357:Drug Synergism; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans
D002945:Cisplatin; D005472:Fluorouracil